Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service bone graft & orthobiologics cases in New Jersey: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 12% on average (190 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 12 | 467 | 33% |
| 2020 | 7 | 301 | 36% |
| 2021 | 9 | 408 | 39% |
| 2022 | 6 | 298 | 41% |
| 2023 | 5 | 290 | 43% |
| 2024 | 3 | 173 | 45% |
| 2025 from claims | – | 155 125–182 | 46% |
| 2026 forecast | – | 157 123–198 | 46% |
| 2027 forecast | – | 159 118–211 | 47% |
| 2028 forecast | – | 162 114–223 | 47% |
| 2029 forecast | – | 164 111–235 | 47% |
| 2030 forecast | – | 166 109–246 | 48% |
Graft add-on codes identify surgeons using biologics across spine and extremity cases. Professional codes (what the surgeon bills): CPT 20930, 20931, 20936, 20937, 20938, 20939.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in New Jersey; 3 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 58% inpatient hospital, 41% hospital outpatient, 1% surgery center.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Pennsylvania | 25 | 1,024−12%/yr | −12%/yr | 0.7 | 0% | 1,010 in 2030−0.2%/yr |
| New York | 21 | 796−5%/yr | −5%/yr | 0.4 | 1% | 810 in 2030+0.2%/yr |
| Massachusetts | 14 | 581−11%/yr | −11%/yr | 0.6 | 0% | 650 in 2030+1.9%/yr |
| Connecticut | 5 | 234−7.1%/yr | −7.1%/yr | 0.7 | 0% | 240 in 2030+0.2%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Debridement & negative-pressure wound therapy | 590 | 129,243−0.9%/yr | −0.9%/yr | 118.71.4× | 49% | 147,900 in 2030+2.3%/yr |
| Skin substitutes & wound grafts | 47 | 11,826+17%/yr | +17%/yr | 7.71.7× | 65% | 21,200 in 2030+10%/yr |
Bone graft & orthobiologics in every state, and its device makers · Every procedure market in New Jersey · Every state · Compare with Pennsylvania
Stryker leads with 30% of company spending on these surgeons in 2025, −4 pts on 2024.
In 2025, 14 companies reported engagement with New Jersey’s surgeons worth $194K in consulting, speaking, meals and travel tied to these products, about $65K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 14 clearances and approvals in the category, 6 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.